Company Overview and News
KUALA LUMPUR (June 18): The FBM KLCI fell 1.07% at mid-morning today as regional markets spooked by the escalating US-China trade spat mostly retreated.
PBLOF 7251 5183 PECGF 7060 UPBMF 4065 5681 2291 1163 1295 2089 5014 KLKBY 2445 5347 3301 1996 TNABY 5819 MYPRY TNABF GEBHF
ONCE again, there is talk of a possible flotation of national oil company Petroliam Nasional Bhd (Petronas). Speculation about such a move makes the rounds every few years. Listing Petronas, it is said, could be one way to help cut down the country’s debt, which has breached the RM1 trillion mark, or a little more than 80% of gross domestic product.
5183 PECGF 4197 5681 6033 PNADF 5347 SMEBF TNABY TNABF BSMAF PNAGF 1818
PETALING JAYA: UBS Global Research has deemed the outcome of GE14 as negative for the Malaysian equity market due to uncertainties over the transition of power and possible changes to existing policies and contracts.
5225 5183 6888 PECGF BATS 4162 AXXTF Q0F IHHHF
KUALA LUMPUR: Petronas Chemicals Group Bhd (PetChem), IHH Healthcare Bhd , Inta Bina Group Bhd, Harrisons Holdings (M) Bhd and GD Express Carrier Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
5008 0078 5225 5183 FORTIS PECGF Q0F IHHHF 532843
“I cannot guarantee to achieve another year of record financial performance. But we will sustain the level of production (output) utilisation of more than 90% in our plants. This is the challenge for us at the moment to maintain it at least at the same production level as last year,” said chairman Datuk Md Arif Mahmood(filepic) at a press conference after its AGM yesterday.
An oil pipeline is laid next to the Vopak-Dialogue oil storage facility (right) and a Refinery and Petrochemical Integrated Development (RAPID) project construction site in Pangerang, Johor October 6, 2015. — Reuters picKUALA LUMPUR, April 18 — The oil and gas (O&G) sector is likely to see a recovery on all fronts this year, having seen its earnings trough in 2017, said RHB Research Institute.
Vietnam shares marked a fresh all-time peak and are on track to end higher for the 18th session in 21. — File picSINGAPORE, April 9 — South-east Asian stock markets inched higher today as a bounceback in US stock futures whetted risk appetite, although heightened trade tensions between the United States and China tempered the gains.
DBSDY D05 5183 PECGF DBSDF SGAPY SNGNF
PETALING JAYA: PRPC Polymers Sdn Bhd, a wholly owned subsidiary of Petronas Chemicals Group Bhd (PetChem), has executed a bridge loan agreement of US$1bil (RM3.92bil) from various local and international banks.
5183 PECGF BSMAF 1818
PETRONAS Chemicals Group (PCG) Berhad's new methanol storage tanks are seen in Tanjung Gelang, Kuantan, March 19, 2018. — Picture by Azinuddin Ghazali KUANTAN, March 19 — PETRONAS Chemicals Group (PCG) Berhad has expanded its methanol distribution service in Kuantan and its surrounding regions with the operational commissioning of two new methanol storage tanks capable of holding 6,000 metric tonnes of the chemical each.
KUALA LUMPUR, March 12 — The petrochemical industry is currently in a sweet spot, given the strong market demand coupled with tight supply in the near term, said Maybank Investment Bank (Maybank IB).
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET